PE20020425A1 - Metodo de anticoncepcion y forma de administracion del mismo - Google Patents
Metodo de anticoncepcion y forma de administracion del mismoInfo
- Publication number
- PE20020425A1 PE20020425A1 PE2001000903A PE2001000903A PE20020425A1 PE 20020425 A1 PE20020425 A1 PE 20020425A1 PE 2001000903 A PE2001000903 A PE 2001000903A PE 2001000903 A PE2001000903 A PE 2001000903A PE 20020425 A1 PE20020425 A1 PE 20020425A1
- Authority
- PE
- Peru
- Prior art keywords
- period
- intake
- administration
- hormone
- free
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 abstract 3
- 239000005556 hormone Substances 0.000 abstract 3
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 abstract 1
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 abstract 1
- 229960001616 chlormadinone acetate Drugs 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 229960000978 cyproterone acetate Drugs 0.000 abstract 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 abstract 1
- 229960004976 desogestrel Drugs 0.000 abstract 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 abstract 1
- 229960003309 dienogest Drugs 0.000 abstract 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 abstract 1
- 229960001910 lynestrenol Drugs 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 abstract 1
- 239000000902 placebo Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
SE REFIERE A UNA FORMA DE ADMINISTRACION HORMONAL QUE CONSTA DE UNA PLURALIDAD DE UNIDADES DE ENVASADO QUE COMPRENDE UN PERIODO DE INGESTA DE DURACION CONSTANTE (22 DIAS) DE UN COMPONENTE HORMONAL TAL COMO 0,5mg A 3mg DE ACETATO DE CLORMADINONA, 1mg A 3mg DE ACETATO DE CIPROTERONA; 0,05mg A 0,2mg DE DESOGESTREL, 1mg A 3mg DE DIENOGEST, 0,035 A 0,1mg DE LEVONOGESTREL; 0,25mg A 3mg DE LINESTRENOL, ENTRE OTROS QUE ACTUAN COMO ANTICONCEPTIVO; PERIODO DE PAUSA DE 4 A 10 DIAS CONSTA DE LA INGESTA DE UN PLACEBO LIBRE DE TODO COMPONENTE HORMONAL O DICHO PERIODO ES LIBRE DE TODA ADMINISTRACION; EL METODO SE CARACTERIZA PORQUE LA DURACION DE LA FASE DE INGESTA DEL PERIODO QUE PRECEDE AL PERIODO DE INGESTA SIGUIENTE ES MENOR QUE CADA UNO DE LOS SIGUIENTES PERIODOS, EL PERIODO DE INGESTA FINAL COMIENZA A MAS TARDAR CON EL DECIMO CICLO DE INGESTA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045380A DE10045380A1 (de) | 2000-09-14 | 2000-09-14 | Verfahren zur Kontrazeption und dessen Darreichungsform |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020425A1 true PE20020425A1 (es) | 2002-06-15 |
Family
ID=7656125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000903A PE20020425A1 (es) | 2000-09-14 | 2001-09-10 | Metodo de anticoncepcion y forma de administracion del mismo |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8076317B2 (es) |
| EP (2) | EP2153849A3 (es) |
| JP (3) | JP2004508398A (es) |
| KR (3) | KR20090033502A (es) |
| CN (1) | CN100560132C (es) |
| AR (1) | AR030737A1 (es) |
| AT (1) | ATE447972T1 (es) |
| AU (2) | AU2001284052B2 (es) |
| BG (2) | BG107625A (es) |
| BR (1) | BR0113902A (es) |
| CA (1) | CA2420292C (es) |
| CZ (1) | CZ2003723A3 (es) |
| DE (2) | DE10045380A1 (es) |
| EA (1) | EA006875B1 (es) |
| EE (1) | EE200300103A (es) |
| HR (1) | HRP20030294A2 (es) |
| HU (1) | HUP0301042A3 (es) |
| IL (2) | IL154521A0 (es) |
| ME (1) | ME00291B (es) |
| MX (1) | MXPA03002070A (es) |
| NO (1) | NO20031152L (es) |
| NZ (1) | NZ524448A (es) |
| PE (1) | PE20020425A1 (es) |
| PL (1) | PL361161A1 (es) |
| SK (1) | SK3102003A3 (es) |
| TW (1) | TWI297271B (es) |
| UA (1) | UA93650C2 (es) |
| UY (1) | UY26932A1 (es) |
| WO (1) | WO2002022110A2 (es) |
| YU (1) | YU19003A (es) |
| ZA (1) | ZA200301359B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004019743B4 (de) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| AU2011226911B2 (en) * | 2004-04-30 | 2014-06-19 | Bayer Intellectual Property Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| DE102004026669A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels |
| DE102004026671A1 (de) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Darreichungsform zur hormonalen Kontrazeption |
| DE102004026670A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| EP1655031A1 (de) | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
| TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
| TW200744610A (en) * | 2005-06-21 | 2007-12-16 | Organon Nv | New regimens for controlled drug delivery devices for contraception |
| US8153616B2 (en) | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
| DE102006003509A1 (de) * | 2006-01-24 | 2007-07-26 | Grünenthal GmbH | Kontrazeptivum |
| EP1930010A1 (de) | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido |
| GB0623813D0 (en) * | 2006-11-29 | 2007-01-10 | Stephenson Group Ltd | Foam reduction |
| DE102007011486A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Arzneimittel umfassend wenigstens ein Gestagen |
| EP2140860A1 (en) * | 2008-07-03 | 2010-01-06 | Bayer Schering Pharma Oy | An improved method of contraception |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| MX2016014281A (es) | 2014-05-22 | 2017-02-22 | Therapeuticsmd Inc | Formulaciones y terapias de reemplazo de combinación de hormonas naturales. |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2365103C3 (de) * | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | V erwendung von Hormonen zur Kontrazeption |
| NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| DK0792152T3 (da) * | 1994-11-22 | 2004-07-12 | Balance Pharmaceuticals Inc | Fremgangsmåder til svangerskabsforebyggelse |
| DE19525017A1 (de) * | 1995-06-28 | 1997-01-02 | Schering Ag | Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption |
| US5922349A (en) * | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| DE69729956T2 (de) | 1996-07-26 | 2004-12-16 | Wyeth | Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält |
| US5898032A (en) * | 1997-06-23 | 1999-04-27 | Medical College Of Hampton Roads | Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy |
-
2000
- 2000-09-14 DE DE10045380A patent/DE10045380A1/de not_active Withdrawn
-
2001
- 2001-09-05 PL PL36116101A patent/PL361161A1/xx not_active Application Discontinuation
- 2001-09-05 BR BR0113902-9A patent/BR0113902A/pt active Search and Examination
- 2001-09-05 SK SK310-2003A patent/SK3102003A3/sk not_active Application Discontinuation
- 2001-09-05 AU AU2001284052A patent/AU2001284052B2/en not_active Ceased
- 2001-09-05 ME MEP-2008-376A patent/ME00291B/me unknown
- 2001-09-05 JP JP2002526362A patent/JP2004508398A/ja not_active Withdrawn
- 2001-09-05 MX MXPA03002070A patent/MXPA03002070A/es active IP Right Grant
- 2001-09-05 CA CA2420292A patent/CA2420292C/en not_active Expired - Fee Related
- 2001-09-05 KR KR1020097005863A patent/KR20090033502A/ko not_active Withdrawn
- 2001-09-05 KR KR1020107010166A patent/KR101240232B1/ko not_active Expired - Fee Related
- 2001-09-05 AU AU8405201A patent/AU8405201A/xx active Pending
- 2001-09-05 HR HR20030294A patent/HRP20030294A2/hr not_active Application Discontinuation
- 2001-09-05 DE DE60140462T patent/DE60140462D1/de not_active Expired - Lifetime
- 2001-09-05 EP EP09014071A patent/EP2153849A3/en not_active Ceased
- 2001-09-05 EP EP01962996A patent/EP1317286B1/en not_active Expired - Lifetime
- 2001-09-05 CN CNB018155707A patent/CN100560132C/zh not_active Expired - Fee Related
- 2001-09-05 EE EEP200300103A patent/EE200300103A/xx unknown
- 2001-09-05 YU YU19003A patent/YU19003A/sh unknown
- 2001-09-05 US US10/380,405 patent/US8076317B2/en not_active Expired - Fee Related
- 2001-09-05 EA EA200300338A patent/EA006875B1/ru not_active IP Right Cessation
- 2001-09-05 IL IL15452101A patent/IL154521A0/xx unknown
- 2001-09-05 UA UA2003043067A patent/UA93650C2/ru unknown
- 2001-09-05 HU HU0301042A patent/HUP0301042A3/hu unknown
- 2001-09-05 KR KR10-2003-7003667A patent/KR20030031185A/ko not_active Ceased
- 2001-09-05 WO PCT/EP2001/010207 patent/WO2002022110A2/en not_active Ceased
- 2001-09-05 AT AT01962996T patent/ATE447972T1/de not_active IP Right Cessation
- 2001-09-05 NZ NZ524448A patent/NZ524448A/en not_active IP Right Cessation
- 2001-09-05 CZ CZ2003723A patent/CZ2003723A3/cs unknown
- 2001-09-10 PE PE2001000903A patent/PE20020425A1/es not_active Application Discontinuation
- 2001-09-11 UY UY26932A patent/UY26932A1/es not_active Application Discontinuation
- 2001-09-12 TW TW090122607A patent/TWI297271B/zh not_active IP Right Cessation
- 2001-09-14 AR ARP010104361A patent/AR030737A1/es not_active Application Discontinuation
-
2003
- 2003-02-18 IL IL154521A patent/IL154521A/en not_active IP Right Cessation
- 2003-02-19 ZA ZA200301359A patent/ZA200301359B/en unknown
- 2003-03-11 BG BG107625A patent/BG107625A/bg unknown
- 2003-03-13 NO NO20031152A patent/NO20031152L/no not_active Application Discontinuation
-
2011
- 2011-11-18 BG BG10111090A patent/BG111090A/bg unknown
- 2011-12-12 US US13/316,887 patent/US8536156B2/en not_active Expired - Fee Related
-
2012
- 2012-09-10 JP JP2012198547A patent/JP2013006866A/ja not_active Withdrawn
-
2013
- 2013-08-09 JP JP2013166891A patent/JP2013241456A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020425A1 (es) | Metodo de anticoncepcion y forma de administracion del mismo | |
| KR960706344A (ko) | 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne) | |
| DE59205986D1 (de) | Ovulationshemmendes Mittel zur hormonalen Kontrazeption | |
| ES2046083B1 (es) | Procedimiento para preparar composiciones de liberacion prolongada. | |
| EA200900491A1 (ru) | Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола | |
| MEP38008A (en) | Drospirenone for hormone replacement therapy | |
| MEP36008A (hr) | Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva | |
| DK0835114T3 (da) | Farmaceutisk kombinationspræparat, kit og fremgangsmåde til den hormonale kontraception | |
| PE20070344A1 (es) | Regimenes para la administracion de las unidades de dosificacion de anticonceptivos monofasicos orales | |
| HRP20090418T1 (hr) | Farmaceutski pripravak koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate | |
| AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
| DE69731092D1 (de) | Orales contrazeptivum | |
| AR049197A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| ATE249222T1 (de) | Biphasische orale verhuetungsmethode und kit die eine kombination von progestin und eines oestrogens enthalten | |
| NO20072893L (no) | Fast, peroralt prevensjonsmiddel | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| AR049196A1 (es) | Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona | |
| DK1652526T3 (da) | Anvendelse af (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-on i behandling af svær depressionslidelse | |
| CA2248841A1 (en) | Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy | |
| DK1937274T3 (da) | Anvendelse af estradiolvalerat i kombination med dienogest til oral behandling af dysfunktionel uterin blødning i enhed med en oral kontraception | |
| PE20091020A1 (es) | Uso de un gestageno en combinacion con un estrogeno y uno o varios excipientes/portadores farmaceuticamente aceptables para la anticoncepcion oral sin lactosa | |
| ECSP003721A (es) | Una composicion farmaceutica para ser usada como anticonceptivo | |
| JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive method | |
| RU2009140372A (ru) | Новый режим с дроспиреноном/17b-эстрадиолом, фармацевтический комбинированный продукт и набор для выполнения этого режима |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |